Combined Results of Two Phase Il Studies of Taxol (Paclitaxel) in Patients with Relapsed or Refractory Lymphomas

References

• Lee R., Cabanillas R, Bodey G., And P., Freireich E. J. A 10-year update of CHOP-Bleo in the treatment of diffuse large-cell lymphoma. Journal of Clinical Oncology 1986; 4: 1455–1461
   PubMed Web of Science ®Google Scholar
• Velasquez W. S., Cabanillas F., Salvador P., McLaughlin P., Fridrik M., Tucker S., Jagannath S., Hagemeister F. B., Redman J. R., Swan F., Barlogie B. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 1988; 71: 117–122
   PubMed Web of Science ®Google Scholar
• Linch D. C., Winfield D., Goldstone A. H., Moir D., Hancock B., McMiilan A., Chopra R., Milligan D., Vaughan Hudson G. Dose intensification with autol-ogous bone marrow transplantation in relapsed and resistant Hodgkin's disease: Result of a BNL 1 randomised trial. Lancet 1993; 341: 1051–1054
   PubMed Web of Science ®Google Scholar
• Brandwein J. M., Callum J., Sutcliffe S. B., Scott J., And G., Keating A. Evaluation of cytoreductive therapy prior to high dose treatment with autologous bone marrow transplantation in relapsed and refractory Hodgkin's disease. Bone Marrow Transplantation 1990; 5: 99–103
   PubMed Web of Science ®Google Scholar
• Goss P., Shepherd F., Scott J. G., Baker M., Sutton D., Sutcliffe S. DICE (dexamethasone. ifosfamide, cisplatin, etoposide) as salvage therapy in Non-Hodgkin's lymphoma. Leukemia and Lymphoma 1988; 18: 123–129
   Google Scholar
• Cabanillas F. Non-Hodgkin's lymphomas: a review of the MD Anderson experience. Seminars in Oncology 1992; 19(1 Suppl 1)11–13
   PubMedGoogle Scholar
• Fisher R. I., Gaynor E. R., Dahlberg S., Oken M. M., Gro-Gan T. M., Mix E. M., Glick J. H., Coltman C., Jr, And A. C., Miller T. P. Comparison of standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. New England Journal of Medicine 1993; 328: 1002–1006
   PubMed Web of Science ®Google Scholar
• Fuchs D., And A., Johnson R. K. Cytologic evidence that Taxol®. an anti-neoplastic agent from taxus brevifolia, acts as a mitotic spindle poison. Cancer Treatment Reports 1978; 62: 1219–1222
   Google Scholar
• Schiff P. B., Fant J., Auster L. A., Honvitz S. B. Effects of Taxol® on cell growth and in vitro microtubule assembly. Journal of Supramolecular Structure (Suppl. 2) 1978; 328
   Google Scholar
• Schiff P. B., Fant J., Horowitz S. B. Promotion of microtubule assembly in vitro by Taxola. Nature 1979; 277: 665–667
   PubMed Web of Science ®Google Scholar
• Schiff P., And B., Horowitz S. B. Taxol® stabilizes microtubules in mouse fibroblast cells. Proceedings of the National Academy of Science 1980; 77: 1561–1565
   PubMed Web of Science ®Google Scholar
• Rowinsky E. K., Onetto N., Canetta R., And M., Arbuck S. G. Taxol®: The first of the taxanes. an important new class of anti-tumor agents. Seminars in Oncology 1992; 19: 646–662
   Google Scholar
• Lenaz L., De Furia M. D. Taxol® a novel natural product with significant anticancer activity. Fitoterapia 1993; 64(1 Suppl.)27–35
   Google Scholar
• Wilson W. H., Chabner B. A., Bryant G., Bates S., Fojo A., Regis J., Jaffe E. S., Steinberg S. M., Goldspiel B. R., Cheson B., And D., Wittes R. E. Phase II study of paclitaxel in refractory and relapsed non-Hodgkin's lymphomas. Journal of Clinical Oncology 1995; 13: 381–386
   PubMed Web of Science ®Google Scholar
• Younes A., Sanis A., Melnyk A., Romaguera J., McLaughlin P., Swan F., Rodriguez M. A., Hagemeister F., Moore D., North L., Smith T., And L., Cabanillas F. Three-hour paclitaxel infusion in patients with refractory and relapsed non-Hodgkin's lymphoma. Journal of Clinical Oncology 1995; 13: 583–587
   PubMed Web of Science ®Google Scholar
• Younes A., Ayoub J-P., Sarris A., Hagemeister F., North L., Pate O., McLaughlin P., Rodriguez M. A., Romaguera J., Kurzrock R., Preti A., Bachier C., Smith T, And Cabanillas F. Paclitaxel activity for the treatment of non-Hodgkin's lymphoma: final report of a phase II trial. British Journal of Haematology 1997; 96: 328–332
   PubMed Web of Science ®Google Scholar
• Press OW, Leblanc M, O'Rouke TI, Gagnet S, Chapman RA, Balcenak SP, Fisher RI. Phase II trial of paclitaxel by 24-hour continuous infusion for relapsed non-Hodgkin's lymphoma: Southwest Oncology Group Trial 9246. Journal of Clinical Oncology 1998; 16: 574–578
   PubMed Web of Science ®Google Scholar
• Eisenhauer E., Ten Bokkel Huinink WW, Swenerton KD, Gianni L, Myles J, Van Der Burg M. E.L., Kerr I, Vermorken JB, Buser K, Colombo N, Bacon M, Santabarbara P, Onetto N, Winograd B, Canetto R. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High -dose versus low-dose and long versus short infusion. Journal of Clinical Oncology 1994; 12: 2654–2666
   PubMed Web of Science ®Google Scholar
• The Non-Hodgkin's Lymphoma Pathologic Classification Project. National Cancer Institute sponsored study of classification of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. Cancer 1982; 49: 2113–2135
   Google Scholar
• Moormeier J. A., Williams S., And F., Golomb H. M. The staging of non-Hodgkin's lymphoma. Seminars in Oncology 1990; 17(1)43–50
   PubMedGoogle Scholar
• World Health Organization. (1979) Handbook for reporting results of cancer treatment. Offset Publication No. 48, WHO, Geneva 1979
   Google Scholar
• Kaplan E., And L., Meier P. Non-parametric estimation from incomplete observations. Journal of the American Statistical Association 1958; 53: 457–481
   Web of Science ®Google Scholar
• Hopfinger G., Heinz R., Pfeilstocker M., Schlogl E., Waldner R., Pittermann E. Paclitaxel in the salvage treatment of Hodgkin's disease and non-Hodgkin's lymphoma. Annals of Oncology 1996; 7: 423–425
   PubMed Web of Science ®Google Scholar
• European Organization for Research on the Treatment of Cancer, Clinical Screening Group. Epipodophyllo-toxin VP-16–213 in treatment of acute leukemias. haema-tosarcomas, and solid tumors. British Medical Journal 1973; 3: 199–202
   Google Scholar
• Warreli R. P., Lee B. G., Kempin S. J., Lacher M. J., Straus D., And J., Young C. J. Effectiveness of methyl-GAG(methylglyoxaLbisguanyhydrazone) in patients with advanced malignant lymphoma. Blood 1981; 57: 1011, 1014.
   PubMed Web of Science ®Google Scholar
• Kantarjian H., Barlogie B., Plunked W., Velasquez W., McLaughlin P., Riggs S., Cabanillas F. High-dose cytosine arabinoside in non-Hodgkin's lymphoma. Journal of Clinical Oncology 1983; 11: 689–694
   Google Scholar
• Hainsworth J. D., Johnson D. H., Frazier S., And R., Greco F. A. Chronic daily administration of oral etoposide in refractory lymphoma. European Journal of Cancer 1990; 26: 818–821
   PubMed Web of Science ®Google Scholar
• Younes A., Romaguera J., Sarris A., North L., Preti A., Hagemeister F., McLaughlin P., Rodriguez M., And A., Cabanillas F. Phase Il trial of infusional taxol and high dose cytoxan with granulocyte colony stimulating factor (filgrastim) for the treatment of relapsedrefractory intermediate grade non-Hodgkin's lymphoma (NHL). Proceedings of the American Society Clinical Oncology. 1996; 15: A1258
   Google Scholar
• Kancheria R, Mannancheril A, Lake DE, Seiter K, Durrani H, Lipschutz M, Navone J, Feldman EJ, Ahmed T. Phase II study of Taxol® and etoposide in relapsedrefractory lymphoma. Proceedings of the American Society Clinical Oncology. 1997; 16: A116
   Google Scholar